Anadys Pharmaceuticals, Inc. (ANDS) has been initiated today with coverage from the research analysts at Brean Murray. Murray begins this new coverage of Anadys Pharmaceuticals with a “hold” rating without a price target, however, Murray noted that Anadys has an attractive risk-reward profile. ‘ANDS’ is currently ranging within Wednesday’s trading range without much definitive direction.
Anadys Pharmaceuticals is slated to release their next earnings report onJuly 28th, 2011 and current EPS consensus estimate expected to be posted is 11 cents to the downside. Their last earnings report was released on May 5th, 2011 and announced negative EPS of 11 cents. ‘ANDS’ is currently trading between its 50 & 200-day moving averages and 2011 is currently a down year for the company.
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The company has market capitalization of $64,000,000 and 57,141,000 shares outstanding. ANDS has a 52-week high of $2.55 with the low being $0.90 cents.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.